Sanofi's Innovative Cardiovascular Drug Dolivir Launched in China

On May 22, 2022, Sanofi China announced that its innovative drug in the cardiovascular field, Dolivi® Clopidogrel Aspirin Tablets (hereinafter referred to as "Doliwei"), was officially launched in China for the prevention of acute coronary syndrome ( ACS) in adult patients with atherothrombotic events.

ACS is a group of clinical syndromes caused by acute myocardial ischemia, mainly due to the rupture or erosion of unstable coronary plaques leading to complete or incomplete occlusive thrombus formation. These include ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA), the former two being collectively referred to as acute myocardial infarction (AMI). Among them, the average hospitalization cost of STEMI patients is 40,500 yuan, and the in-hospital mortality rate has also risen from 3.29% in 2019 to 3.48%, which has brought a heavy burden to China's cardiovascular disease and has become a major public health problem.

In clinical treatment, dual antiplatelet therapy (DAPT) based on aspirin combined with clopidogrel is the antithrombotic basis for ACS patients, but there is still a current status of low compliance. According to the CPACS2 study, of the 15,141 adult hospitalized patients with ACS included in the study, only 19.4% continued DAPT to 12 months.

The data show that Dolivit® is a multi-active component preparation based on the drug interaction theory, that is, using the beneficial factors of drug interaction to improve the overall therapeutic effect of the drug and improve patient compliance1. This result has also been confirmed in multiple clinical studies around the world:

A 30-day French clinical study to evaluate the use of antiplatelet therapy in patients with ACS undergoing percutaneous coronary intervention. The study included a total of 390 patients, and the final results confirmed that the non-adherence rate of the SPC group was 7%, which was significantly lower than the 17% of the clopidogrel plus aspirin combination group.

A 12-month Italian community study to evaluate the use of dual antiplatelet therapy in patients with ACS. A total of 26,834 patients were included in the study, and the final results confirmed that the compliance rate in the SPC group was 81.5%, higher than the 72.9% in the clopidogrel plus aspirin monotherapy group.